Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 34 of 151

  1. CF101 1mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  2. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  3. CF102

    Can-Fite BioPharma

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    2 trials

  4. CFWY003A12201

    Novartis Pharmaceuticals

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  5. CG0070

    CG Oncology

    Bladder Cancer

    phase 2 mab completed

    1 trial

  6. CG0070

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 2 mab completed

    1 trial

  7. CGIA632A12201

    Novartis Pharmaceuticals

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  8. CGT4859

    Cogent Biosciences

    Intrahepatic Cholangiocarcinoma (Icc)

    phase 2 small molecule active

    1 trial

  9. CGT9486

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule completed

    1 trial

  10. CGT9486, CGT9486

    Cogent Biosciences

    Advanced Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  11. CGVV858A12101

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  12. CGXV813B12201

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  13. CHALLENGE

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  14. CHF6001 DPI

    Chiesi Farmaceutici S.p.A

    Asthma

    phase 2 small molecule active

    1 trial

  15. CHIMERA

    Istituto Gentili S.r.l.

    Malignant Pleural Mesothelioma

    phase 2 small molecule active

    1 trial

  16. CHO-H01

    Cho Pharma

    Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  17. CHOP+selinexor+5-Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  18. CHRMS19-0129

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  19. CHRONVAC-C®

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule active

    1 trial

  20. CI-581aa

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  21. CIALIS 5 mg film-coated tablets

    The George Institute

    sexual/ erectile function in women and men after treatment for rectal cancer

    phase 2 small molecule active

    1 trial

  22. CIBI3009A101

    Talion

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  23. CID-103

    CASI Pharmaceuticals

    Chronic Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  24. CIK

    The First People's Hospital of Lianyungang

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

  25. CINC280A2X02B

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  26. CINRYZE

    Takeda

    Hereditary Angioedema

    phase 2 mab completed

    1 trial

  27. CINRYZE

    Takeda

    Hereditary Angioedema (HAE)

    phase 2 mab completed

    1 trial

  28. CINRYZE with rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Hereditary Angioedema

    phase 2 mab completed

    1 trial

  29. CINRYZE with rHuPH20

    Takeda

    Hereditary Angioedema (HAE)

    phase 2 mab completed

    1 trial

  30. CIRCULATE-SPAIN-01

    The George Institute

    Localised Colon Cancer (stage II-III)

    phase 2 small molecule active

    1 trial

  31. CJDQ443A12101

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  32. CJDQ443E12101

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  33. CJSB462B12201

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  34. CJSB462C12201

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  35. CL1-65487-003

    The George Institute

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule active

    1 trial

  36. CL1-95012-001

    The George Institute

    Soild Tumors

    phase 2 small molecule active

    1 trial

  37. CL1-95029-002

    The George Institute

    MSI-H/dMMR Gastric cancer, MSI-H/dMMR Gastroesophageal-junction Cancer

    phase 2 small molecule active

    1 trial

  38. CL1-95035-001

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  39. CLARITY-PT01

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  40. CLBS03 Low Dose

    LISATA THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 2 mab completed

    1 trial

  41. CLBS12

    LISATA THERAPEUTICS, INC.

    Critical Limb Ischemia

    phase 2 mab completed

    1 trial

  42. CLBS14 (low-dose)

    LISATA THERAPEUTICS, INC.

    Myocardial Ischemia

    phase 2 mab completed

    1 trial

  43. CLBS16

    LISATA THERAPEUTICS, INC.

    Coronary Microvascular Dysfunction

    phase 2 mab terminated

    2 trials

  44. CLCI699C2203

    Recordati Ireland

    Cushing's disease

    phase 2 small molecule active

    1 trial

  45. CLEAN-DUCT

    The George Institute

    Extrahepatic cholangiocarcinoma (eCCA)

    phase 2 small molecule active

    1 trial

  46. CLEE011Q12101

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  47. CLEE011X2107

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  48. CLEE011X2X01B

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.